Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of b...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 964 3720

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

Iightning Nov. 21 at 5:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

0 · Reply

alexx013 Nov. 20 at 3:05 PM

$INMB 2 bucks soon

1 · Reply

Iightning Nov. 20 at 3:41 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

1 · Reply

alexx013 Nov. 19 at 3:37 PM

$INMB time to go north

0 · Reply

Iightning Nov. 19 at 11:19 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

0 · Reply

Philippians4919 Nov. 18 at 4:49 AM

$INMB just gonna buy this at 2026

1 · Reply

BigSwingMoe Nov. 18 at 3:17 AM

$INMB another fake bull... shorts been on this for over a month... especially the sand people

2 · Reply

wsakyle2 Nov. 18 at 12:52 AM

$INMB Shocked to see this green almost my whole watchlist is red, crypto seems to be crashing hard too

1 · Reply

CcBuyer Nov. 17 at 5:46 PM

$INMB

0 · Reply

BigSwingMoe Nov. 17 at 3:54 AM

$INMB pretty obvious the people in here are fake bulls

0 · Reply

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Oct 30, 2025, 11:16 PM EDT - 21 days ago

INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:05 PM EDT - 21 days ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Oct 14, 2025, 7:00 AM EDT - 5 weeks ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Aug 8, 2025, 3:23 PM EDT - 3 months ago

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:00 AM EDT - 3 months ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 4 months ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 4 months ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jul 4, 2025, 11:48 PM EDT - 4 months ago

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Jul 4, 2025, 9:20 AM EDT - 5 months ago

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jun 30, 2025, 4:05 PM EDT - 5 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 11:52 AM EDT - 5 months ago

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

Jun 30, 2025, 7:36 AM EDT - 5 months ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 5 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 4:50 PM EDT - 5 months ago

INmune Bio: Finding Pay Dirt In Alzheimer's?

Jun 27, 2025, 12:16 PM EDT - 5 months ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 27, 2025, 10:38 AM EDT - 5 months ago

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

Jun 26, 2025, 4:00 PM EDT - 5 months ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

Jun 16, 2025, 11:29 AM EDT - 5 months ago

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

May 15, 2025, 5:28 PM EDT - 6 months ago

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

May 10, 2025, 3:57 AM EDT - 6 months ago

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 7 months ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 7 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 14, 2025, 8:00 AM EDT - 7 months ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Mar 27, 2025, 8:15 PM EDT - 8 months ago

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 8 months ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Mar 21, 2025, 1:15 PM EDT - 8 months ago

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

PNW PRI

Mar 18, 2025, 4:31 PM EDT - 8 months ago

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

Feb 12, 2025, 7:00 AM EST - 10 months ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 7:00 AM EST - 10 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jan 2, 2025, 8:52 AM EST - 11 months ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Dec 30, 2024, 3:20 PM EST - 11 months ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 4, 2024, 9:00 AM EST - 1 year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 8:09 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 30, 2024, 5:04 AM EDT - 1 year ago

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 26, 2024, 8:00 AM EDT - 1 year ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 3, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Aug 1, 2024, 11:50 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Jul 29, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 23, 2024, 8:45 AM EDT - 1 year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Jul 8, 2024, 6:12 AM EDT - 1 year ago

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Iightning Nov. 21 at 5:44 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

0 · Reply

alexx013 Nov. 20 at 3:05 PM

$INMB 2 bucks soon

1 · Reply

Iightning Nov. 20 at 3:41 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

1 · Reply

alexx013 Nov. 19 at 3:37 PM

$INMB time to go north

0 · Reply

Iightning Nov. 19 at 11:19 AM

1ightning® Options Trade Alert (Actionable) | Buy $INMB Dec 19 $2 Call | Enter: $0.15 Exit: $0.28 | Profit: 88.30% ROI | https://1ightning.com

0 · Reply

Philippians4919 Nov. 18 at 4:49 AM

$INMB just gonna buy this at 2026

1 · Reply

BigSwingMoe Nov. 18 at 3:17 AM

$INMB another fake bull... shorts been on this for over a month... especially the sand people

2 · Reply

wsakyle2 Nov. 18 at 12:52 AM

$INMB Shocked to see this green almost my whole watchlist is red, crypto seems to be crashing hard too

1 · Reply

CcBuyer Nov. 17 at 5:46 PM

$INMB

0 · Reply

BigSwingMoe Nov. 17 at 3:54 AM

$INMB pretty obvious the people in here are fake bulls

0 · Reply

lisaparsons Nov. 17 at 12:28 AM

$INMB please explain how Stocktwits says extremely bullish. I’m curious.

0 · Reply

tuckerabbott Nov. 15 at 5:11 AM

$INMB dumpster fire.

0 · Reply

BigSwingMoe Nov. 14 at 2:31 PM

$INMB has been shorted to death... it's been short... cover... rinse and repeat for over a month... the MACD... RSI... and order history don't lie. $VCIG $BULL $OMEX $MCD

1 · Reply

BigSwingMoe Nov. 14 at 2:25 PM

$INMB short... cover... rinse and repeat. That's what's been going on here for a month straight.

1 · Reply

biglossagain Nov. 14 at 12:44 PM

$INMB dropped like a stone after the leaked report. Now it’s keeps going down. It looks to me that some know it’s going down to 0.50$ with the large amount of shorting on this stock

0 · Reply

wsakyle2 Nov. 14 at 3:01 AM

$INMB Might add a bit tmr, i know things have been rough and i hooe some where able to average down, news 🗞️,patternship talks, vote on the 17th, its due for a run here

1 · Reply

lisaparsons Nov. 13 at 4:29 PM

$INMB isnt the meeting just for options for executives. the 10qs all state no money for further development and no sight of revenue. we know they are in early stages however, there is no indication of looking for partners. This is scary already lost a fortune here , not even worth selling at this point. i dont understand how analysts could have a buy on this. can anyone clarify. wishing best for all of us . that reverse split killed a lot of us. please make my day in a see of red. blessings,

1 · Reply

NotInvestmentAdviceBro Nov. 13 at 3:09 PM

$INMB holders — quick reminder to vote your shares. To find your proxy: • Search email for “ProxyVote” or “Broadridge” • Check broker app → Messages / Action Needed • Or call your broker and ask for your proxy link Vote however you want — just vote.

0 · Reply

Fanatic01 Nov. 13 at 5:52 AM

$INMB

0 · Reply

Measure4Measure Nov. 13 at 4:25 AM

$INMB This looks dead.... lost a fortune here ...

1 · Reply

RadioIsotope25 Nov. 12 at 6:56 PM

$INMB Looks like shell now. 50 cent target

1 · Reply

BigSwingMoe Nov. 12 at 6:12 PM

$INMB rumors about a partnership...!!??!

0 · Reply

Market Cap	40.14M
Revenue (ttm)	10,000.00
Net Income (ttm)	-42.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-420,800.03%
Debt to Equity Ratio	0.00

Volume	250,227
Avg Vol	426,040
Day's Range	N/A - N/A
Shares Out	26.59M
Stochastic %K	35%
Beta	0.95
Analysts	Sell
Price Target	$12.67